Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Axel Hinzpeter

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Expert Opinion on Pharmacotherapy|April 26, 2006
Neuroprotective agents in schizophrenia and affective disordersMichael Krebs, Karolina Leopold, Axel Hinzpeter, et al.
Expert Opinion on Pharmacotherapy|May 26, 2006
Current schizophrenia drugs: efficacy and side effectsMichael Krebs, Karolina Leopold, Axel Hinzpeter, et al.
Journal of Clinical Psychopharmacology|November 25, 2010
Levetiracetam for the treatment of alcohol withdrawal syndrome: a multicenter, prospective, randomized, placebo-controlled trialChristoph Richter, Axel Hinzpeter, Folkhard Schmidt, et al.
Journal of Hepatology|May 12, 2005
Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis CMartin Schaefer, Markus Schwaiger, Andrea S Garkisch, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 3, 2009
Depressive mood changes and psychiatric symptoms during 12-month low-dose interferon-alpha treatment in patients with malignant melanoma: results from the multicenter DeCOG trialSarah Heinze, Friederike Egberts, Susanne Rötzer, et al.
Hepatology (Baltimore, Md.)|August 3, 2007
Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effectsMartin Schaefer, Axel Hinzpeter, Ariane Mohmand, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Expert Opinion on Pharmacotherapy|April 26, 2006
Neuroprotective agents in schizophrenia and affective disordersMichael Krebs, Karolina Leopold, Axel Hinzpeter, et al.
Expert Opinion on Pharmacotherapy|May 26, 2006
Current schizophrenia drugs: efficacy and side effectsMichael Krebs, Karolina Leopold, Axel Hinzpeter, et al.
Journal of Clinical Psychopharmacology|November 25, 2010
Levetiracetam for the treatment of alcohol withdrawal syndrome: a multicenter, prospective, randomized, placebo-controlled trialChristoph Richter, Axel Hinzpeter, Folkhard Schmidt, et al.
Journal of Hepatology|May 12, 2005
Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis CMartin Schaefer, Markus Schwaiger, Andrea S Garkisch, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 3, 2009
Depressive mood changes and psychiatric symptoms during 12-month low-dose interferon-alpha treatment in patients with malignant melanoma: results from the multicenter DeCOG trialSarah Heinze, Friederike Egberts, Susanne Rötzer, et al.
Hepatology (Baltimore, Md.)|August 3, 2007
Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effectsMartin Schaefer, Axel Hinzpeter, Ariane Mohmand, et al.
Pageof 1